Abstract
The authors report on the results of their clinical investigation of SBTPC, an ester bond compound of β-lactamase inhibitor sulbactam (SBT) and ampicillin (ABPC).
The antibacterial activity of SBPTC was compared to those of ABPC, cefazolin (CEZ) and cephalothin (CET) in a total of 168 clinically isolated strains of S. aureus, E. coli, K. pneumoniae, E. cloacae, S. marcescens, Proteussp. and P. aeruginosa. SBTPC exhibited greater antibacterial activity against S. aureus, S. faecalis, E. coli and Proteus sp. than ABPC.
Clinical evaluation was carried out in 16 patients with respiratory tract infection (RTI) and one patient withurinary tract infection (UTI). Response was excellent and good in 11 cases out of 16 RTI and good in one case of UTI.
As a side effect, rash observed in 2 cases but adverse reaction disappeared within one week following discontinuance of administration.
